Navigation Links
Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
Date:4/25/2012

RICHMOND, Calif., April 25, 2012 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its first quarter 2012 financial results on Wednesday, May 2, 2012, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 73837943. Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under "Events and Presentations," http://investor.sangamo.com/events.cfm. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on May 2, 2012 to 11:59 p.m. ET on May 9, 2012. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 73837943.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. It has ongoing Phase 2 and Phase 1/2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia, and a program in Parkinson's disease. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs). Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire to develop therapeutics for hemophilia and other monogenic diseases and has established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com.

ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
2. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
3. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
4. Sangamo BioSciences Announces Presentation at the Lazard Capital Markets 8th Annual Healthcare Conference
5. Sangamo BioSciences Reports Third Quarter 2011 Financial Results
6. Sangamo BioSciences Announces Third Quarter 2011 Conference Call and Webcast
7. Sangamo BioSciences Announces Presentation at the 18th Annual Newsmakers in the Biotech Industry Conference
8. Sangamo BioSciences Announces Presentation at the 2011 UBS Global Life Sciences Conference
9. Sangamo BioSciences Reports Second Quarter 2011 Financial Results
10. Sangamo BioSciences Announces Efficient Generation of Transgenic Pigs Using Zinc Finger Nuclease (ZFN) Technology
11. Sangamo BioSciences Announces Second Quarter 2011 Conference Call and Webcast
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/28/2017)... -RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (FRA:P6P2) ("RepliCel" ... clinical data from its phase 1/2 tendon repair study investigating ... (RCT-01) as a treatment for Achilles tendinosis. ... The clinical trial ... 6 months and showed no serious adverse events related to ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... fight against cancer, autoimmune disease and more through a single-cell precision engineering platform, ... proteomics analysis platform developed in the laboratory of Dr. James Heath at ...
(Date:3/27/2017)... , March 27, 2017  The global ... for 2016, according to a new report from ... lab testing is performed to evaluate disease progression, ... therapy, among other reasons.  The healthcare market research ... , provides an overview of the medical ...
(Date:3/27/2017)... ... March 27, 2017 , ... A research team ... vascular grafts in JoVE’s Video Journal, the world’s first peer-reviewed scientific video journal. ... of treating coronary artery disease (CAD). Lam is an assistant professor at the ...
Breaking Biology Technology:
(Date:3/2/2017)... March 2, 2017 Australian stem cell and ... CYP), has signed an agreement with the Monash Lung ... Biomedicine Discovery Institute and Department of Pharmacology at Monash ... further preclinical study to support the use of Cymerus™ ... Asthma is a chronic, long term ...
(Date:2/28/2017)... Feb. 28, 2017   Acuant , a leading ... announces significant enhancements to new and core technologies building ... products include mobile and desktop Acuant FRM TM ... - a real time manual review of identity documents ... provides the fastest and most accurate capture software to ...
(Date:2/28/2017)... Spanien, 27. Februar 2017  EyeLock LLC, ein marktführendes ... seine erstklassige biometrische Lösung zur Iris-Erkennung auf ... X16 LTE auf dem Mobile World Congress ... Qualcomm-Stand in Halle 3, Stand 3E10, vorstellen. ... Sicherheitsplattform Qualcomm Haven™ – eine Kombination aus ...
Breaking Biology News(10 mins):